Saman Eskandarzadeh
Overview
Explore the profile of Saman Eskandarzadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramezani-Rad P, Cottrell C, Marina-Zarate E, Liguori A, Landais E, Torres J, et al.
bioRxiv
. 2025 Feb;
PMID: 39896562
A protective vaccine against HIV will likely need to induce broadly neutralizing antibodies (bnAbs) that engage relatively conserved epitopes on the HIV envelope glycoprotein (Env) trimer. Nearly all vaccine strategies...
2.
Yousefpour P, Zhang Y, Maiorino L, Melo M, Arainga Ramirez M, Kumarapperuma S, et al.
PNAS Nexus
. 2024 Dec;
3(12):pgae529.
PMID: 39677368
Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out...
3.
Madden P, Marina-Zarate E, Rodrigues K, Steichen J, Shil M, Ni K, et al.
bioRxiv
. 2024 Dec;
PMID: 39651117
Rare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions to protective immunity. However, rare naive B cells infrequently participate in immune responses. We...
4.
Yousefpour P, Zhang Y, Maiorino L, Melo M, Arainga Ramirez M, Kumarapperuma S, et al.
bioRxiv
. 2024 Sep;
PMID: 39253464
Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out...
5.
Schiffner T, Phung I, Ray R, Irimia A, Tian M, Swanson O, et al.
Nat Immunol
. 2024 Jun;
25(7):1307.
PMID: 38877179
No abstract available.
6.
Schiffner T, Phung I, Ray R, Irimia A, Tian M, Swanson O, et al.
Nat Immunol
. 2024 May;
25(6):1073-1082.
PMID: 38816615
A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of...
7.
Wang X, Cottrell C, Hu X, Ray R, Bottermann M, Villavicencio P, et al.
Sci Immunol
. 2024 May;
9(95):eadn0622.
PMID: 38753808
Germline-targeting (GT) protein immunogens to induce VRC01-class broadly neutralizing antibodies (bnAbs) to the CD4-binding site of the HIV envelope (Env) have shown promise in clinical trials. Here, we preclinically validated...
8.
Cottrell C, Hu X, Lee J, Skog P, Luo S, Flynn C, et al.
Sci Transl Med
. 2024 May;
16(748):eadn0223.
PMID: 38753806
A protective HIV vaccine will likely need to induce broadly neutralizing antibodies (bnAbs). Vaccination with the germline-targeting immunogen eOD-GT8 60mer adjuvanted with AS01 was found to induce VRC01-class bnAb precursors...
9.
Phung I, Rodrigues K, Marina-Zarate E, Maiorino L, Pahar B, Lee W, et al.
Nat Commun
. 2023 Nov;
14(1):7107.
PMID: 37925510
Adjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency...
10.
Leggat D, Cohen K, Willis J, Fulp W, deCamp A, Kalyuzhniy O, et al.
Science
. 2022 Dec;
378(6623):eadd6502.
PMID: 36454825
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B...